Plain-English translation of NCT06748651 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a small, early-stage trial testing a new treatment called for jaw joint osteoarthritis — a condition where the cartilage in your jaw joint gradually breaks down, causing pain and difficulty moving your jaw. is made from specially modified immune cells designed to calm inflammation in the joint. The study will give you a single injection directly into your jaw joint and then follow you for a year to see if it's safe and whether it helps reduce your symptoms.
Jaw joint osteoarthritis can cause chronic pain and limit how well you can eat and speak, and standard treatments don't work for everyone. This trial is exploring whether this new cell-based medication might offer relief for people who haven't had success with other options.
You likely qualify if…
You likely don't qualify if…
You will come in for a single treatment day, during which you'll receive one injection of the medication directly into your jaw joint. After that, you'll return for follow-up visits and monitoring over the course of one year so the research team can track whether the treatment is safe and whether your symptoms improve. The study is small (only 6 participants) and is designed to carefully watch for any safety concerns.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Israel
Phase
Safety & dosing
Sponsor
Dr. Amit Druyan
Collaborators
Sheba Medical Center
Enrollment target
~6 participants
Started
December 2024
Primary completion
February 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 60 Years
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Amit Druyan, Dr.
Dr. Amit Druyan
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.